BioInformant

Your Global Leader in Stem Cell Market Research

Home » cord blood » Page 13

Nohla Therapeutics Secures $45 Million to Develop Cord Blood Treatment for Leukemia

By Leave a Comment

Nohla Therapeutics Announces Closing of $45 Million Series B Financing

Proceeds to Support the Development of Dilanubicel (NLA101) and Additional Platform Programs

Seattle, WA; May 15, 2018 – Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. [Read more…]

Geographical Differences in Cord Blood Banking

By Leave a Comment

This article explores geographical differences in cord blood banking within key regions of the world. While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know international boundaries.

The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.

In this article:

[Read more…]

ExCellThera Developing Cord Blood Expansion Technology ECT-001 for Multiple Myeloma

By Leave a Comment

ECT-001 is basis of new clinical trial for multiple myeloma

MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a new Phase I/II clinical trial in patients with multiple myeloma. The study will enroll up to 20 high-risk, multiple myeloma patients from the Hôpital Maisonneuve-Rosemont in Montreal, Canada. [Read more…]

Who is Global Cord Blood Corporation (Previously China Cord Blood Corporation)?

By 1 Comment

Global Cord Blood Corporation (NYSE: CO), previously named China Cord Blood Corporation (CCBC), became the first cord blood bank in China when it began operations in 2003. It was the first cord blood bank in China to receive ISO900 certification and is AABB accredited. It is also the largest cord blood banking operator in China in terms of geographical coverage and the only bank operating with multiple licenses.

On February 7, 2018, the company’s Board of Directors announced that it was pursuing shareholder approval to change the Company’s name from “China Cord Blood Corporation” to “Global Cord Blood Corporation” (GCBC). The name change reflects the company’s growing interest in international expansion. [Read more…]

Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time

By Leave a Comment

The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch  or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.

PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0